Key clinical point: Though intestinal metaplasia and dysplasia in the cardia were common in patients with Barrett’s esophagus before treatment, successful endoscopic eradication therapy lessened the risk of recurrence.

Major finding: In a group of patients who had been successfully treated for Barrett’s esophagus, 15% had cardia intestinal metaplasia or dysplasia.

Study details: A prospective study of two groups: patients who had undergone successful endoscopic eradication therapy for Barrett’s esophagus, and patients undergoing endoscopic eradication therapy.

Disclosures: The study was funded by an American Gastroenterological Association Research Scholar Award and CSA Medical. The authors reported no conflicts of interest.